Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:EARS
- CUSIP: N/A
- Web: www.aurismedical.com
Capitalization:- Market Cap: $38.92 million
- Outstanding Shares: 44,329,000
Average Prices:- 50 Day Moving Avg: $0.73
- 200 Day Moving Avg: $0.85
- 52 Week Range: $0.60 - $5.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.83
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.25 per share
- Price / Book: 3.55
Profitability:- EBIDTA: ($31,310,000.00)
- Return on Equity: -168.61%
- Return on Assets: -80.46%
Debt:- Debt-to-Equity Ratio: 0.85%
- Current Ratio: 3.35%
- Quick Ratio: 3.35%
Misc:- Average Volume: 317,310 shs.
- Beta: 0.67
- Short Ratio: 5.95
Frequently Asked Questions for Auris Medical Holding AG (NASDAQ:EARS)
What is Auris Medical Holding AG's stock symbol?
Auris Medical Holding AG trades on the NASDAQ under the ticker symbol "EARS."
How were Auris Medical Holding AG's earnings last quarter?
Auris Medical Holding AG (NASDAQ:EARS) issued its quarterly earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.08. View Auris Medical Holding AG's Earnings History.
When will Auris Medical Holding AG make its next earnings announcement?
Where is Auris Medical Holding AG's stock going? Where will Auris Medical Holding AG's stock price be in 2017?
3 brokers have issued 12-month price objectives for Auris Medical Holding AG's stock. Their predictions range from $4.00 to $5.00. On average, they expect Auris Medical Holding AG's share price to reach $4.50 in the next year. View Analyst Ratings for Auris Medical Holding AG.
What are analysts saying about Auris Medical Holding AG stock?
Here are some recent quotes from research analysts about Auris Medical Holding AG stock:
- 1. Needham & Company LLC analysts commented, "EARS reported 4Q16 financials and update its three ongoing development programs. The next key data catalyst for EARS will be ph 3 HEALOS results for AM-111 (hearing loss) in 3Q17. The study, which should complete enrollment in 2Q17, is the first of two AM-111 pivotal studies in hearing loss. The Keyzilen program will first report results from the open-label studies (AMPACT-1 and 2) in 2Q17 while the recently modified TACCT3 study is on track to have top-line results in 1Q18. EARS plans to evaluate AM-125 (Meniere's disease/vertigo) in an additional ph 1 trial (initiating in 2H17) prior to discussing a regulatory pathway with regulatory authorities. The current EARS market valuation appears to place minimal to no value on any of the ongoing clinical programs.We maintain our Buy rating and adjust our $PT to $4 (from $5)." (3/14/2017)
- 2. According to Zacks Investment Research, "Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. " (1/10/2017)
Who are some of Auris Medical Holding AG's key competitors?
Some companies that are related to Auris Medical Holding AG include ImmuPharma PLC (IMM), Aldeyra Therapeutics (ALDX), ProNAi Therapeutics (SRRA), Leap Therapeutics (LPTX), Flex Pharma (FLKS), Synthetic Biologics (SYN), Intec Pharma (NTEC), Aeglea BioTherapeutics (AGLE), Verona Pharma Plc (VRP), Endocyte (ECYT), Xenon Pharmaceuticals (XENE), Actinium Pharmaceuticals (ATNM), Egalet Corporation (EGLT), Avacta Group Plc (AVCT), Imprimis Pharmaceuticals (IMMY), Rexahn Pharmaceuticals (RNN), Motif Bio PLC (MTFB) and Akari Therapeutics PLC (AKTX).
Who are Auris Medical Holding AG's key executives?
Auris Medical Holding AG's management team includes the folowing people:
- Thomas Meyer, Chairman of the Board, Chief Executive Officer
- Hernan Levett, Chief Financial Officer
- Anne Sabine Zoller, General Counsel
- Cindy McGee, Head of Investor Relations and Corporate Communications
- Andrea Braun, Head of Regulatory and Quality Affairs
- Thomas Jung M.D., Ph.D., Chief Development Officer
- Bettina Mirella Stubinski, Chief Medical Officer
- James I. Healy M.D. Ph.D., Non-Executive Independent Vice Chairman of the Board
- Wolfgang Arnold, Non-Executive Independent Director
- Oliver Kubli, Non-Executive Independent Director
Who owns Auris Medical Holding AG stock?
How do I buy Auris Medical Holding AG stock?
Shares of Auris Medical Holding AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical Holding AG's stock price today?
One share of Auris Medical Holding AG stock can currently be purchased for approximately $0.88.
MarketBeat Community Rating for Auris Medical Holding AG (NASDAQ EARS)MarketBeat's community ratings are surveys of what our community members think about Auris Medical Holding AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Auris Medical Holding AG (NASDAQ:EARS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $4.50 (412.53% upside) |
Analysts' Ratings History for Auris Medical Holding AG (NASDAQ:EARS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/1/2017 | Roth Capital | Reiterated Rating | Buy | $5.00 | Low |  |
| 3/14/2017 | Needham & Company LLC | Lower Price Target | Buy | $5.00 -> $4.00 | High | |
| 11/11/2016 | JMP Securities | Reiterated Rating | Hold | | N/A | |
| 6/15/2016 | Leerink Swann | Reiterated Rating | Buy | $12.00 | N/A | |
| 6/10/2016 | Jefferies Group LLC | Reiterated Rating | Buy | | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for Auris Medical Holding AG (NASDAQ:EARS)Earnings History by Quarter for Auris Medical Holding AG (NASDAQ EARS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/16/2017 | | ($0.19) | | | | | N/A | |
| 5/11/2017 | 3/31/2017 | ($0.14) | ($0.22) | | | View | N/A | |
| 3/14/2017 | 12/31/2016 | ($0.29) | ($0.16) | | | View | N/A | |
| 11/10/2016 | Q316 | ($0.28) | ($0.23) | | | View | Listen | |
| 5/11/2016 | Q116 | ($0.23) | ($0.26) | | | View | Listen | |
| 3/14/2016 | Q415 | ($0.29) | ($0.16) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.28) | ($0.16) | | | View | Listen | |
| 8/19/2015 | Q215 | ($0.23) | ($0.36) | | | View | Listen | |
| 5/28/2015 | Q115 | ($0.22) | ($0.29) | | | View | Listen | |
| 3/19/2015 | Q4 | ($0.23) | ($0.17) | | | View | Listen | |
| 12/3/2014 | Q3 | ($0.24) | ($0.14) | | | View | N/A | |
| 9/15/2014 | Q2 2014 | ($0.34) | ($0.29) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Auris Medical Holding AG (NASDAQ:EARS)Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.31 EPS
Dividend History for Auris Medical Holding AG (NASDAQ:EARS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Auris Medical Holding AG (NASDAQ:EARS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Auris Medical Holding AG (NASDAQ:EARS)
Latest Headlines for Auris Medical Holding AG (NASDAQ:EARS)
| Source: |
|
| Date | Headline |
|---|
 | Auris Medical Completes Acquisition of AM-125 Assets - GlobeNewswire (press release)
www.globenewswire.com - July 20 at 3:24 PM |
 | Auris Medical Completes Acquisition of AM-125 Assets
finance.yahoo.com - July 20 at 3:24 PM |
 | ARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELG
www.nasdaq.com - July 6 at 4:51 AM |
 | Auris Medical Holding (EARS) Reports Complete Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
www.streetinsider.com - July 6 at 4:51 AM |
 | BRIEF-Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafness
www.reuters.com - July 5 at 11:49 PM |
| Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness - GlobeNewswire (press release)
globenewswire.com - July 5 at 6:48 PM |
| Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
finance.yahoo.com - July 5 at 6:47 PM |
 | Auris Medical Holding AG (EARS) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - July 3 at 6:25 PM |
| Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - GlobeNewswire (press release)
globenewswire.com - June 22 at 5:20 PM |
| Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - Nasdaq
www.nasdaq.com - June 22 at 10:13 AM |
| Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris
finance.yahoo.com - June 22 at 10:13 AM |
 | Auris Medical Holding (EARS) Updates On Clinical Stage Project Development (Key Opinion Leader Event) - Slideshow
seekingalpha.com - June 19 at 11:44 PM |
| ValuEngine Downgrades Auris Medical Holding AG (EARS) to Strong Sell
www.americanbankingnews.com - June 4 at 7:56 PM |
| Auris Medical Holding AG (EARS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 2 at 8:32 PM |
| Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City - GlobeNewswire (press release)
globenewswire.com - May 31 at 4:51 PM |
| Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City
finance.yahoo.com - May 31 at 9:47 AM |
 | How These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma
www.bizjournals.com - May 18 at 10:34 AM |
| Auris Medical Holding AG (EARS) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 16 at 7:20 AM |
| Auris Medical Holding AG (EARS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 11:48 AM |
| BRIEF-Auris Medical reports Q1 loss per share chf 0.22
www.reuters.com - May 11 at 10:34 PM |
| Edited Transcript of EARS earnings conference call or presentation 11-May-17 12:00pm GMT
finance.yahoo.com - May 11 at 10:34 PM |
| Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 8:57 AM |
| Investor Network: Auris Medical Holding AG to Host Earnings Call
finance.yahoo.com - May 11 at 8:57 AM |
| Auris reports 1Q loss
finance.yahoo.com - May 11 at 8:57 AM |
 | Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
feeds.benzinga.com - May 11 at 6:43 AM |
| Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open ... - Nasdaq
www.nasdaq.com - May 10 at 6:40 AM |
| Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open ... - GlobeNewswire (press release)
globenewswire.com - May 9 at 4:50 PM |
| Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open-Label Extension Study
finance.yahoo.com - May 9 at 4:50 PM |
| Auris Medical Holding AG (EARS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 9 at 7:02 AM |
| Auris Medical Holding AG (EARS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 8 at 4:36 PM |
| Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11,
www.nasdaq.com - May 5 at 3:03 AM |
| Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017 - GlobeNewswire (press release)
www.globenewswire.com - May 4 at 10:01 AM |
| Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017
finance.yahoo.com - May 4 at 10:01 AM |
| Auris Medical Holding AG (EARS) Given News Impact Score of -0.03
www.americanbankingnews.com - May 4 at 9:44 AM |
| Brokerages Expect Auris Medical Holding AG (EARS) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - May 3 at 5:58 PM |
| Auris Medical Holding AG (EARS) Given Daily News Impact Rating of 0.05
www.americanbankingnews.com - May 1 at 6:30 PM |
| Auris Medical Company Overview
seekingalpha.com - April 28 at 5:55 PM |
| Auris Medical Holding AG (EARS) Earning Somewhat Critical Press Coverage, Study Shows
www.americanbankingnews.com - April 28 at 12:38 PM |
| Auris Medical Holding (EARS) Announces Results from Keyzilen AMPACT2 Open-Label Extension Study
www.streetinsider.com - April 24 at 4:44 PM |
| Auris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study - GlobeNewswire (press release)
globenewswire.com - April 24 at 8:45 AM |
| Auris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study
feeds.benzinga.com - April 24 at 8:28 AM |
| Auris Medical Holding AG (EARS) Receives News Impact Rating of 0.07
www.americanbankingnews.com - April 21 at 1:23 PM |
| Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies - Reuters
www.reuters.com - April 21 at 12:09 PM |
| Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies
finance.yahoo.com - April 20 at 5:00 PM |
| Auris Medical Holding AG (EARS) Getting Very Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 18 at 10:18 AM |
| Auris Medical Holding AG (EARS) Short Interest Update
www.americanbankingnews.com - April 15 at 7:08 AM |
| Auris Medical Holding AG (EARS) Getting Somewhat Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 14 at 8:46 PM |
| Auris Medical Holding AG (EARS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 13 at 1:20 PM |
| Roth Capital Begins Coverage on Auris Medical Holding AG (EARS)
www.americanbankingnews.com - April 13 at 1:00 PM |
| Premarket analyst action - healthcare
seekingalpha.com - April 13 at 11:33 AM |
Auris Medical Holding AG (EARS) Chart for Monday, July, 24, 2017
